I am not too worried about the EFS trial, it seems pretty small, but I am more wary around the pivotal study next year.
Is there any guidance around the size of the trial/recruitment, the centres that would do it, costs and timeframe?
And also regarding marketability - given that the benefits of an Anteris valve become clearer with time (measured in years not months) - when can Anteris start marketing and making some actual sales? Apologies if these questions have been answered in the thread, I had a look and didn't see them. Fwiw I held from 2015-2021, debating getting back in.
AGM questions for submission to management, page-10
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$6.15 |
Change
0.150(2.50%) |
Mkt cap ! $95.31M | |||
| Open | High | Low | Value | Volume |
| $6.00 | $6.15 | $6.00 | $41.13K | 6.816K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 165 | $6.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.20 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| AVR (ASX) Chart |